Terms: = Breast cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Prognosis
137 results:
1. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
2. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
3. Investigation of Genetic Alterations Associated With Interval breast cancer.
Rodriguez J; Grassmann F; Xiao Q; Eriksson M; Mao X; Bajalica-Lagercrantz S; Hall P; Czene K
JAMA Oncol; 2024 Mar; 10(3):372-379. PubMed ID: 38270937
[TBL] [Abstract] [Full Text] [Related]
4. Association Between a History of breast cancer and Decreased Thyroid cancer-specific Mortality.
Lin S; Wang Z; Xing M
J Clin Endocrinol Metab; 2024 Apr; 109(5):1222-1230. PubMed ID: 38064679
[TBL] [Abstract] [Full Text] [Related]
5. High PGAP3 expression is associated with lymph node metastasis and low CD8
Hao N; Li M; Wang J; Song Y; Zhao Y; Zhang L; Yang X; Chen L; Ma J; Jia Q; Sui F
Pathol Res Pract; 2023 Nov; 251():154890. PubMed ID: 37839361
[TBL] [Abstract] [Full Text] [Related]
6. Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.
Wang J; Tan J; Wu B; Wu R; Han Y; Wang C; Gao Z; Jiang D; Xia X
J Nanobiotechnology; 2023 Oct; 21(1):374. PubMed ID: 37833748
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological features and prognosis of patients with HER2-low breast cancer.
Yang X; Li Y; Lu X; Ren X; Hua B
BMC Cancer; 2023 Sep; 23(1):914. PubMed ID: 37770874
[TBL] [Abstract] [Full Text] [Related]
8. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative breast cancer.
Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
[TBL] [Abstract] [Full Text] [Related]
9. Integrated network pharmacology, bioinformatics, and molecular docking to explore the mechanisms of berberine regulating autophagy in breast cancer.
Huang B; Wen G; Li R; Wu M; Zou Z
Medicine (Baltimore); 2023 Sep; 102(36):e35070. PubMed ID: 37682166
[TBL] [Abstract] [Full Text] [Related]
10. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
11. Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.
Zakaria NH; Hashad D; Saied MH; Hegazy N; Elkayal A; Tayae E
Hum Genomics; 2023 May; 17(1):43. PubMed ID: 37202799
[TBL] [Abstract] [Full Text] [Related]
12. Multigene germline testing usefulness instead of BRCA1/2 single screening in triple negative breast cancer cases.
Arranz-Ledo M; Lastra E; Abella L; Ferreira R; Orozco M; Hernández L; Martínez N; Infante M; Durán M
Pathol Res Pract; 2023 Jul; 247():154514. PubMed ID: 37201465
[TBL] [Abstract] [Full Text] [Related]
13. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract] [Full Text] [Related]
14. Liposomal atm siRNA delivery for enhancing triple-negaitive breast cancer immune checkpoint blockade therapy.
Yu D; Wang H; Liu H; Xu R
J Biomater Appl; 2023 May; 37(10):1835-1846. PubMed ID: 37016537
[TBL] [Abstract] [Full Text] [Related]
15. Potential Phytochemicals for Prevention of Familial breast cancer with BRCA Mutations.
Shahiwala AF; Khan GA
Curr Drug Targets; 2023; 24(6):521-531. PubMed ID: 36918779
[TBL] [Abstract] [Full Text] [Related]
16. Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
17. Identification of novel characteristic biomarkers and immune infiltration profile for the anaplastic thyroid cancer via machine learning algorithms.
Li C; Dong X; Yuan Q; Xu G; Di Z; Yang Y; Hou J; Zheng L; Chen W; Wu G
J Endocrinol Invest; 2023 Aug; 46(8):1633-1650. PubMed ID: 36725810
[TBL] [Abstract] [Full Text] [Related]
18. Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1).
Roser E; Harter P; Zocholl D; Denschlag D; Chekerov R; Wimberger P; Kurzeder C; Hasenburg A; Muallem MZ; Mustea A; Emons G; Zeimet AG; Beck F; Arndt T; Brucker SY; Kommoss S; Heitz F; Welz J; Egger EK; Kalder M; Buderath P; Klar M; Marth C; Ulrich UA; Weigel M; Traub L; Anthuber C; Strauss H; Hanker L; Link T; Kubiak K; Melekian B; Hornung D; Pölcher M; Lampe B; Krauß T; Keilholz U; Flörcken A; Pietzner K; Sehouli J
Int J Gynecol Cancer; 2023 Feb; 33(2):223-230. PubMed ID: 36631151
[TBL] [Abstract] [Full Text] [Related]
19. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract] [Full Text] [Related]
20. STAT3 and PD-L1 are negatively correlated with atm and have impact on the prognosis of triple-negative breast cancer patients with low atm expression.
Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
[TBL] [Abstract] [Full Text] [Related]
[Next]